Spero Therapeutics Inc
NASDAQ:SPRO
Spero Therapeutics Inc
NASDAQ:SPRO
Price:
2.37
USD
0.85%
Market Closed
Market Cap:
$133.5m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Spero Therapeutics Inc
NASDAQ:SPRO
|
US |
|
Signature Resources Ltd
XTSX:SGU
|
CA |
|
CNO Financial Group Inc
NYSE:CNO
|
US |
|
E
|
EVN Finance JSC
VN:EVF
|
VN |
|
Toshin Holdings Co Ltd
TSE:9444
|
JP |
|
C
|
Cathay Consolidated Inc
TWSE:1342
|
TW |
|
T
|
True Partner Capital Holding Ltd
HKEX:8657
|
HK |
|
C
|
China Industrial Steel Inc
OTC:CDNN
|
US |
|
G
|
General Mills Inc
XETRA:GRM
|
US |
|
O
|
Oriental Hotels Ltd
NSE:ORIENTHOT
|
IN |
|
S
|
Sierra Rutile Holdings Ltd
ASX:SRX
|
AU |
Relative Value
The Relative Value of one
SPRO
stock under the Base Case scenario is
hidden
USD.
Compared to the current market price of 2.37 USD,
Spero Therapeutics Inc
is
hidden
.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
SPRO Relative Value
HIDDEN
Multiples Across Competitors
SPRO Competitors Multiples
Spero Therapeutics Inc Competitors
Spero Therapeutics Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
Spero Therapeutics Inc
NASDAQ:SPRO
|
133.5m USD | 3.3 | -3 | -1.9 | -1.9 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 690 872.8 | -160 127.7 | -194 446.1 | -192 227.3 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
362.8B USD | 5.9 | 86.7 | 14.4 | 20 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
187.8B USD | 5.1 | 24.3 | 14.1 | 14.1 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
171.4B USD | 5.8 | 20.2 | 12.6 | 15.6 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
113.9B USD | 9.5 | 28.8 | 21.7 | 22.6 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 091 | -533.6 | -581 | -565.5 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
78.4B USD | 5.5 | 17.4 | 12.8 | 14.6 | |
| AU |
|
CSL Ltd
ASX:CSL
|
67.2B AUD | 3.1 | 34.4 | 11.4 | 14.3 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.1 | -61.8 | -66.6 | -60.1 | |
| NL |
|
argenx SE
XBRU:ARGX
|
36B EUR | 10.1 | 32.6 | 35.1 | 35.8 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
